UBB 2000
Alternative Names: UBB-2000Latest Information Update: 19 Jan 2021
At a glance
- Originator UNITY Biotechnology
- Class Eye disorder therapies; Small molecules
- Mechanism of Action TIE-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration; Diabetic macular oedema; Diabetic retinopathy
Most Recent Events
- 19 Jan 2021 Preclinical trials in Age-related macular degeneration in USA (unspecified route) (UNITY Biotechnology pipeline, January 2021)
- 19 Jan 2021 Preclinical trials in Diabetic macular oedema in USA (unspecified route) (UNITY Biotechnology pipeline, January 2021)
- 19 Jan 2021 Preclinical trials in Diabetic retinopathy in USA (unspecified route) (UNITY Biotechnology pipeline, January 2021)